Yang Hao, Zheng Wei, Shuai Xiao, Chang Rui-Min, Yu Lei, Fang Feng, Yang Lian-Yue
Liver Cancer Laboratory, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Department of Geratic Surgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Oncotarget. 2015 Sep 29;6(29):27736-50. doi: 10.18632/oncotarget.4811.
By comparing the expression profiles of miRNAs in different subtypes of HCC, we identified miR-424 as a HCC related miRNA. We found that the expression of miR-424 was significantly decreased in HCC tissues and six liver cancer cell lines. Significantly, its expression levels were correlated with tumor size, multiple nodules, vein invasion, TNM stage and overall survival of HCC. We showed that up-regulated miR-424 suppressed HCC cell proliferation in vivo and in vitro. Multi-pathway reporter arrays suggested that miR-424 suppressed the pRb-E2F pathway. Consistently, Akt3 and E2F3 were identified as the targets of miR-424 as evidenced by that ectopic miR-424 expression suppressed Akt3 and E2F3 expressions. Silencing Akt3 and E2F3 by siRNA pheno-copied the effect of ectopic miR-424 on HCC growth. Whereas, overexpression of Akt3 and E2F3 attenuated the effect of miR-424 on HCC growth. Together, our data demonstrated a tumor suppressor role for miR-424 in HCC development and progression with therapeutic implications. The strong correlation of miR-424 expression with HCC patient survival suggests that miR-424 could be a valuable biomarker for HCC prognosis.
通过比较肝癌不同亚型中miRNA的表达谱,我们鉴定出miR-424是一种与肝癌相关的miRNA。我们发现,miR-424在肝癌组织和六种肝癌细胞系中的表达显著降低。重要的是,其表达水平与肝癌的肿瘤大小、多发结节、静脉侵犯、TNM分期及总生存期相关。我们发现,上调miR-424在体内和体外均能抑制肝癌细胞增殖。多通路报告基因阵列显示,miR-424抑制pRb-E2F通路。同样,Akt3和E2F3被鉴定为miR-424的靶标,异位表达miR-424可抑制Akt3和E2F3的表达,这证明了这一点。用siRNA沉默Akt3和E2F3可模拟异位表达miR-424对肝癌生长的影响。而Akt3和E2F3的过表达减弱了miR-424对肝癌生长的影响。总之,我们的数据证明了miR-424在肝癌发生发展中具有肿瘤抑制作用,并具有治疗意义。miR-424表达与肝癌患者生存率的强相关性表明,miR-424可能是肝癌预后的一个有价值的生物标志物。